Knowledge HQ

Publications
Publications

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial [High Res Image]

High-resolution graphical abstract of the KRAS G12V TCR-T trial. It traces PBMC isolation, lentiviral TCR transduction, rapid expansion in a G-Rex 500M vessel, and infusion after lymphodepletion. Outcomes shown: low-grade CRS, one complete response, and anti-TCR antibody driving rejection.
Download Now
Publications

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Allogeneic MSLN CAR-NKT cells were generated from cord blood CD34+ HSPCs. They outperformed conventional CAR-T cells in ovarian cancer, homed to tumors, modulated the microenvironment, minimized cytokine release syndrome and GvHD, and resisted allorejection. Expansion used G-Rex 6M well plates.
Download Now
Publications

DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors

Desmoglein 2 is universally overexpressed on transformed epithelial cells but junction-restricted in normal tissue. Anti-DSG2 CAR-T cells lysed varied solid tumor lines and eliminated colon, pancreatic, lung, prostate, breast and liver tumors in vivo. Cells expanded 10 days in a G-Rex 6M system.
Download Now
Publications

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial

Single-arm phase 1/2 trial NCT04146298 treated five recurrent pancreatic cancer patients with autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V TCR; three had repeat infusions. Products were rapidly expanded in G-Rex 500 flasks and rested in G-Rex 24-well plates (Wilson Wolf).
Download Now
Publications

Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia

PanErbB CAR-T cells were made by lentiviral transduction of Fanconi anemia and healthy donor T cells and killed HNSCC models, offering an alternative to toxic radio-chemotherapy. Cells were expanded in G-Rex GMP-scalable devices (Wilson Wolf) under hypoxia, with viability above 70%.
Download Now
Publications

Engineering "physically optimized" T cells for increased sampling of complex tumor microenvironments

Constitutively active RhoA raises cortical contractility, activation, migration and tumor sampling in T cells while lowering exhaustion markers. CAR T cells engage carcinoma cells faster and improve pancreatic tumor control in vivo. Sorted T cells were expanded 3 extra days in 24-well G-Rex.
Download Now
Publications

Preclinical comparison of non-signaling domain in CD19 CAR T cell with interleukin-7 receptor alpha signaling domain

Three non-signaling domain designs were tested in a CD19 CAR with 4-1BB and IL-7R alpha. IgG2/CD28 lowered expression and function, CD8/CD8 gave the highest density, and IgG2.CH3/CD28 raised cytokines and persistence. CAR T cells were cultured in G-Rex plates (Wilson Wolf).
Download Now
Publications

Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders

HDR editing integrates a functional FOXP3 cDNA into CD4+ T cells to create engineered Tregs for IPEX. The study reports targeting efficiency, enrichment, off-target analysis and in vivo suppression. Enriched EngTregs were expanded 7 days in G-Rex flasks with CD3/CD28 beads, IL-2 and rapamycin.
Download Now
Publications

High throughput, automated and fully contained cytokine release assay using primary human CD4+ T cells

Pfizer describes an automated, fully contained cytokine release assay using primary human CD4+ T cells, screening up to 15,000 compounds weekly. Isolated T cells expand 6- to 8-fold in 7 days. G-Rex 10 open-system flasks (Wilson Wolf) supply the 4-day expansion step of the protocol.
Download Now
Publications

Repurposing base editors for targeted knock-in and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations

Base editors are repurposed for targeted knock-in plus simultaneous multiplex knockouts, yielding allogeneic CAR T cells with minimal translocations. Edited CAR T cells were expanded in G-Rex bioreactors (ScaleReady), and reagents were supported by the ScaleReady G-Rex Grant Initiative.
Download Now
Publications

IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity

Retroviral IL-18, alone or with IL-15, was co-expressed with a GD2 CAR in human NKT cells. IL-18 reprogrammed metabolism and raised cytotoxicity, proliferation and cytokine output over IL-15 alone, outperforming CAR-T cells. NKTs were stimulated and expanded in 24-well G-Rex plates.
Download Now
Publications

FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer

FOXM1 epitopes were immunogenic on HLA-A*02:01, A*24:02 and A*23:01 and endogenously presented. TCR-engineered T cells showed confirmed specificity, reduced tumor growth and prolonged survival in NSCLC models. T cells were cultured with IL2 in G-Rex 24-well plates (Wilson Wolf) for 4 to 8 days.
Download Now

ScaleReady is a joint venture between Wilson Wolf Manufacturing and Bio-Techne.